Source-grounded facts extracted from Surrozen, Inc./DE's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Surrozen, Inc./DE shareholders approved Advisory vote on the preferred frequency of advisory approval of executive compensation at the 2026-05-13 meeting.
“The Company’s stockholders approved, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company’s named executive officers, by the following votes: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 7,068,763 0 21,636 3 654,267”
Surrozen, Inc./DE shareholders approved Advisory vote on executive compensation at the 2026-05-13 meeting.
“The Company’s stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K compensation tables and narrative discussions, by the following votes: For Against Abstain Broker Non-Votes 6,312,815 776,738 849 654,267”
Surrozen, Inc./DE shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for 2026 at the 2026-05-13 meeting.
“The voting results with respect to the proposal to ratify the appointment of Ernst & Young LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026 were as follows: For Against Abstain 7,744,358 284 27”
Surrozen, Inc./DE shareholders approved Election of two Class II directors to serve until 2029 Annual Meeting at the 2026-05-13 meeting.
“The votes cast for or withheld for each director nominee, and the number of broker non-votes, were as follows: Director Nominee For Withheld Broker Non-Votes Mace Rothenberg, M.D. 5,982,651 1,107,751 654,267 David J. Woodhouse, Ph.D. 7,087,293 3,109 654,267”
Surrozen, Inc./DE reported the quarter ended March 31, 2026 results: net income $127.5 million, EPS ($11.65) per share.
“Net loss was $127.5 million, or ($11.65) per share for the quarter ended March 31, 2026”
Surrozen, Inc./DE reported fourth quarter and full year 2025 results: revenue $0.5 million and $3.5 million for the quarter and year ended December 31, 2025.
“On March 23, 2026, Surrozen, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025.”
Tim Kutzkey was appointed as Class I Director at Surrozen, Inc./DE.
“Upon the recommendation of the Nominating and Corporate Governance Committee, on March 26, 2025, Tim Kutzkey, Ph.D., was appointed to serve as a Class I director of the Company’s Board of Directors”
Tim Kutzkey resigned as Director at Surrozen, Inc./DE.
“On June 30, 2024, Tim Kutzkey, Ph.D. notified Surrozen, Inc. of his resignation as a member of our board of directors and from all committees of the board of directors on which he served, effective as of June 30, 2024.”
Surrozen, Inc./DE reported the quarter ended March 31, 2024 results: net income $8.8 million.
“Net loss for the first quarter ended March 31, 2024 was $8.8 million, as compared to $14.3 million for the same period in 2023.”
Surrozen, Inc./DE entered into Securities Purchase Agreement with certain institutional investors and management valued at aggregate gross proceeds of approximately $17.5 million (effective 2024-04-01).
“On April 1, 2024, Surrozen, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”), with certain institutional investors (the “Investors”) and management (together with the Investors, the “Purchasers”)”
Charles Williams was appointed as Chief Operating Officer at Surrozen, Inc./DE.
“On February 1, 2024, Surrozen, Inc. appointed Charles Williams, our current Chief Financial Officer, to the concurrent position of Chief Operating Officer, effective as of February 1, 2024.”
Surrozen, Inc./DE: Effected a one-for-fifteen reverse stock split of common stock via a Certificate of Amendment to the Certificate of Incorporation (effective 2023-12-13).
“On December 13, 2023, Surrozen, Inc., a Delaware corporation (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Amendment”), to effect a one-for-fifteen (1:15) reverse stock split of its outstanding common stock, effective as of December 13, 2023 (the “Reverse Stock Split”).”
Surrozen, Inc./DE shareholders approved Approval of an amendment to the certificate of incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock at the 2023-12-07 meeting.
“Proposal 1: Approval of an amendment to the certificate of incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock, as disclosed in the proxy statement. For Against Abstain 16,220,409 784,459 534”
Surrozen, Inc./DE reported the third quarter ended September 30, 2023 results: net income $10.4 million.
“Net loss for the third quarter ended September 30, 2023 was $10.4 million, as compared to $13.4 million for the same period in 2022.”
Surrozen, Inc./DE: Amended quorum requirements for stockholder meetings from majority to at least one-third of voting power (effective 2023-10-10).
“On October 10, 2023, the board of directors of Surrozen, Inc. (the “Company”) amended and restated the Company’s Bylaws (the “Bylaws”), effective immediately.”
Surrozen, Inc./DE reported second quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $9.4 million, as compared to $13.9 million for the same period i.
“Net loss for the second quarter ended June 30, 2023 was $9.4 million, as compared to $13.9 million for the same period in 2022.”
Wen-Chen Yeh resigned as Chief Scientific Officer at Surrozen, Inc./DE.
“On July 14, 2023, Surrozen, Inc. and Wen-Chen Yeh, M.D., Ph.D., our Chief Scientific Officer, agreed that in connection with our planned restructuring and reduction-in-force, Dr. Yeh will cease serving as our Chief Scientific Officer and join our Scientific Advisory Board effective as of July 31, 2023.”
Surrozen, Inc./DE received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“July 5, 2023, Surrozen, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company is eligible for an additional 180 calendar day period, or until January 2, 2024, to regain compliance with the minimum $1.00 bid price per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). In the letter, Nasdaq noted that the Company’s common stock had not regained compliance with the Minimum Bid Req”
Surrozen, Inc./DE shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-18 meeting.
“The voting results with respect to the proposal to ratify the appointment of Ernst & Young LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 were as follows: For Against Abstain 18,240,296 499,008 4,440 Accordingly, the Company’s shareholders ratified the appointment of Ernst & Young LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Surrozen, Inc./DE shareholders approved Election of three nominees to serve as directors until 2026 Annual Meeting at the 2023-05-18 meeting.
“The votes cast for or withheld for each director nominee were as follows: Director Nominee For Withheld Broker Non-Votes Shao-Lee Lin, M.D., Ph.D. 10,955,283 4,205,346 3,087,115 Mace Rothenberg, M.D. 11,843,735 3,316,894 3,087,115 David J. Woodhouse, Ph.D. 17,744,296 3,316,894 3,087,115 Accordingly, the three nominees listed above were each elected to serve as a director of the Company until the 2026 Annual Meeting of Shareholders and until the election and qualification of his or her successor, subject to his or her earlier death, resignation or removal.”
Surrozen, Inc./DE reported first quarter ended March 31, 2023 results: net income $14.3 million.
“Surrozen, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2023.”
Eric Bjerkholt was appointed as Class I Director at Surrozen, Inc./DE.
“On April 5, 2023, the board of directors of Surrozen, Inc. appointed Eric Bjerkholt to serve as a Class I director”
Surrozen, Inc./DE reported the year ended December 31, 2022 results: revenue $12.5 million.
“Collaboration and License Revenue for the fourth quarter and year ended December 31, 2022, was $12.5 million”
Surrozen, Inc./DE reported the fourth quarter ended December 31, 2022 results: revenue $12.5 million.
“Collaboration and License Revenue for the fourth quarter and year ended December 31, 2022, was $12.5 million”
Surrozen, Inc./DE received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“January 4, 2023, Surrozen, Inc. received a written notice from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying us that on January 3, 2023, the average closing price of our common stock over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days to regain compliance with the Minimum Bid Requirement (the “Grace Period”), subject t”
Surrozen, Inc./DE reported the quarter ended September 30, 2022 results: net income $13.4 million.
“Net loss for the third quarter ended September 30, 2022 was $13.4 million, as compared to $14.0 million for the same period in 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.